Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

The Hepatitis C Treatment Pipeline

September 2011

 < Prev  |  1  |  2  |  3  |  4  |  5  |  6 

References

  1. Lok A, Gardiner D, Lawitz E, et al. Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. (Abstract 418) 46th Meeting of the European Association for the Study of the Liver. Berlin, Germany. March 30-April 3, 2011.
  2. Jacobson IM, McHutchison JG, Dusheiko G, et al; ADVANCE Study Team. Telaprevir in combination with peginterferon alfa-2a and ribavirin in genotype 1 HCV treatment naive patients: final results of phase III ADVANCE study. (Abstract LB-2) 61st Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. October 29-November 2, 2010.
  3. Poordad F, McCone J Jr, Bacon BR, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31;364(13):1195-206.
  4. Sherman KE, Flamm SL, Afdhal NH, et al; ILLUMINATE Study Team. Telaprevir in combination with peginterferon alfa-2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response; final results of phase III ILLUMINATE study. (Abstract LB-1) 61st Annual Meeting of the American Association for the Study of Liver Diseases. Boston, Massachusetts. October 29-November 2, 2010.
  5. Zeuzem S, Andreone P, Pol S, et al. REALIZE trial final results: telaprevir-based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response, or relapse to peginterferon/ribavirin (Opening and General Session 1) 46th Meeting of the European Association for the Study of the Liver. Berlin, Germany. March 30-April 3, 2011.
  6. Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E Clinical Pharmacology of BOC: Metabolism, Excretion, and Drug-Drug Interaction. (Abstract 118). 18th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts. February 27-March 2nd 2011.
  7. van Heeswijk R, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic Interactions between ARV Agents and the Investigational HCV Protease Inhibitor TVR in Healthy Volunteers. (Abstract 119) 18th Conference on Retroviruses and Opportunistic Infections. Boston. February 27-March 2, 2011.
  8. Bacon BR, Gordon SC, Lawitz E, et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic hepatitis C genotype 1 infection. N Engl J Med. 2011 Mar 31; 364 (13): 1207-17.
  9. Zeuzem S, Arora S, Bacon B, et al; on behalf of the EMERGE Study Group Pegylated Interferon-lambda (PegIFN-λ) shows superior viral response with improved safety and tolerability versus PegIFNα-2a in HCV patients (G1/2/3/4): Emerge Phase IIB through week 12. (Abstract 1360) 46th Meeting of the European Association for the Study of the Liver. Berlin, Germany. March 30-April 3, 2011.


Additional Resources

www.clinicaltrials.gov
www.hepatitisCadvocate.org
www.hivandhepatitis.com
www.natap.org

 < Prev  |  1  |  2  |  3  |  4  |  5  |  6 


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Treatment Action Group and HIV i-Base. It is a part of the publication 2011 Pipeline Report.
 
See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More on Hepatitis C Drugs in Development

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement